AUTHORS
John Hanna, MD, Omer Karrar, MD2, Nitin Jain, MD3, Hannah Goulart, MD4, Roberta Santos Azevedo, MD5, Fadi G. Haddad, MD6, Alex Bataller, MD, PhD7, Jennifer Marvin-Peek, MD8, Sanam Loghavi, MD9, Eitan Kugler, MD PhD10, Rebecca Garris11, Farhad Ravandi, MD12, Hagop Kantarjian, MD13, Elias Jabbour, MD14, Nicholas Short, MD15
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Most relapses in adults with acute lymphoblastic leukemia (ALL) occur within 3 years of achieving first complete remission (CR1). However, the conditional risk of relapse among patients (pts) who maintain CR1, and the clinicobiologic features and outcomes of very late relapses, remain incompletely characterized. We evaluated cumulative incidence of relapse (CIR), conditional relapse risk after sustained CR1, and the characteristics and post-relapse outcomes of very late relapses.
Methods: We retrospectively analyzed 1,370 adults with newly diagnosed ALL treated at our institution from 1992 through 2022 who achieved CR or CR with incomplete hematologic recovery (CRi) after frontline therapy. CIR was calculated from CR1, censoring at death without relapse or last follow-up. Landmark analyses estimated dynamic changes in relapse risk among pts in continuous CR1 at 1, 2, 3, 4, and 5 years. Very late relapse was defined as first relapse ≥5 years after CR1. Overall response rates (ORR, i.e CR + CRi) to salvage therapy, relapse-free survival (RFS), and overall survival (OS) after first relapse were compared by CR1 duration.
Results: Median age at diagnosis was 44 years (range, 18–88); 1,150 pts (84%) had B-ALL, 170 (12%) T-ALL, and 50 (4%) unspecified lineage. Among pts with B-ALL, 310 (27%) had Philadelphia chromosome-positive (Ph+) disease. Overall, 520 pts (38%) relapsed after a median remission duration of 14.6 months. CIR at 1, 2, 3, 4, and 5 years was 18%, 29%, 34%, 39%, and 41%. The 5-year CIR was similar in B-ALL and T-ALL (41% for both; P=0.46).
Among pts in continuous CR1 at 1, 2, 3, 4, and 5 years (n=992, 805, 705, 594 and 515, respectively), the risk of relapse during the subsequent 5 years decreased to 31%, 20%, 15%, 10%, and 6%, respectively. Similar conditional risks of relapse at these landmarks were observed in B- vs. T-ALL and in Ph-negative vs. Ph+ ALL.
Among 298 pts who received first salvage at our institution and had complete outcome data, the ORR was 66%. ORR increased with longer CR1 duration: 56% (62/111), 71% (86/122), 72% (31/43), and 77% (17/22) for CR1 durations of <1, 1 to <3, 3 to <5, and ≥5 years (P=0.04), with the greatest difference between CR1 duration <1 vs. ≥1 year. Similarly, 5-year post-relapse OS increased with longer CR1 duration: 6%, 20%, 36%, and 51% (P<.0001), as did 5-year RFS: 8%, 19%, 28%, and 46%, respectively (P<.0001).
Overall, 33 pts (2% of all responders, 6% of all relapses) had very late relapse (i.e. CR1 duration ≥5 years); 6 had CR1 duration >10 years. 28 (85%) were B-ALL and 5 (15%) were T-ALL. Detailed post-relapse characterization was available for 30 pts, of whom 9 (30% overall, 32% of B-ALL relapses) had Ph+ ALL. Relapse was bone marrow (BM)-only in 22 pts (73%), isolated extramedullary (EM) in 6 pts (20%; CNS, n=2; non-CNS, n=4), and BM + EM in 2 pts (7%). 3/5 pts (60%) with baseline EM disease had EM involvement at very late relapse. 8 pts (27% of very late relapses; 47% of responders to salvage therapy) proceeded to allogeneic SCT in CR2. Paired diagnostic and relapse karyotypes were evaluable in 13 pts with Ph-negative B-ALL or T-ALL, 9 (69%) of whom had new cytogenetic abnormalities at time of relapse. Among the 9 pts with Ph+ ALL and very late relapse, 1 pt had Ph-negative, near-triploid, TP53-mutated ALL after a CR1 duration of 24 years (the longest in the cohort), suggesting a clonally unrelated second ALL rather than true relapse. 2/4 pts had an ABL1 kinase domain mutation at relapse (V299L and T315I in 1 pt each).
Conclusions: In adults with ALL in CR1, relapse risk declined significantly with increasing CR duration but was still 6% in pts in continuous remission for 5 years. These conditional relapse risk estimates may inform prognostic discussions with pts and guide optimal disease monitoring frequency. Post-salvage response and survival improved with longer CR1 duration, highlighting the strong prognostic impact of CR1 duration on post-relapse outcomes in ALL. Very late relapses (i.e. relapse after CR1 ≥5 years) were characterized by clinically relevant shifts in disease distribution, including CNS or non-CNS EM involvement in >25% of pts, and high response rates and OS after salvage therapy, with post-relapse outcomes similar to historical expectations of frontline pts. Future studies are needed to better understand the biological mechanisms underlying very late relapse and its risk after contemporary immunotherapy-based frontline regimens.
DISCLOSURES
John Hanna, MD: No relevant conflicts of interest to declare.